Total Payments
$3,540
2024 Payments
$27.96
Companies
34
Transactions
131
Medicare Patients
3,728
Medicare Billing
$672,173
Payment Breakdown by Category
Food & Beverage$2,350 (66.4%)
Travel$905.30 (25.6%)
Education$285.21 (8.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,350 | 123 | 66.4% |
| Travel and Lodging | $905.30 | 3 | 25.6% |
| Education | $285.21 | 5 | 8.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $1,338 | 18 | $0 (2020) |
| Novocure Inc. | $386.19 | 7 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $234.02 | 10 | $0 (2021) |
| Genentech USA, Inc. | $197.32 | 9 | $0 (2019) |
| Amgen Inc. | $195.54 | 12 | $0 (2021) |
| Incyte Corporation | $158.28 | 5 | $0 (2021) |
| Janssen Biotech, Inc. | $124.91 | 9 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $100.57 | 7 | $0 (2021) |
| Lilly USA, LLC | $95.84 | 8 | $0 (2020) |
| Celgene Corporation | $76.24 | 5 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $27.96 | 1 | ABBVIE INC. ($27.96) |
| 2021 | $192.87 | 13 | Janssen Biotech, Inc. ($49.83) |
| 2020 | $191.04 | 12 | Amgen Inc. ($52.25) |
| 2019 | $2,150 | 53 | Merck Sharp & Dohme Corporation ($1,254) |
| 2018 | $145.92 | 8 | AstraZeneca Pharmaceuticals LP ($52.41) |
| 2017 | $832.97 | 44 | Novocure Inc. ($266.89) |
All Payment Transactions
131 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $27.96 | General |
| Category: ONCOLOGY | ||||||
| 06/28/2021 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $11.86 | General |
| Category: Oncology | ||||||
| 06/24/2021 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $28.88 | General |
| Category: Oncology | ||||||
| 06/07/2021 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $15.89 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/28/2021 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $12.74 | General |
| Category: Oncology | ||||||
| 05/26/2021 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $14.11 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 04/27/2021 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $12.07 | General |
| Category: Oncology | ||||||
| 04/21/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.20 | General |
| Category: Oncology | ||||||
| 04/19/2021 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $12.24 | General |
| Category: Oncology | ||||||
| 04/09/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $13.26 | General |
| Category: Oncology | ||||||
| 04/06/2021 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $12.03 | General |
| Category: Oncology | ||||||
| 03/31/2021 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $21.91 | General |
| Category: Oncology | ||||||
| 01/13/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $11.76 | General |
| Category: Oncology | ||||||
| 03/12/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: Oncology | ||||||
| 03/09/2020 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $12.09 | General |
| Category: Oncology | ||||||
| 03/03/2020 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $13.06 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 02/20/2020 | Amgen Inc. | Prolia (Biological), XGEVA | Food and Beverage | In-kind items and services | $22.70 | General |
| Category: Bone Health | ||||||
| 02/18/2020 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $28.25 | General |
| Category: Oncology | ||||||
| 02/13/2020 | Lilly USA, LLC | CYRAMZA (Drug), VERZENIO | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: Oncology | ||||||
| 02/12/2020 | Amgen Inc. | Prolia (Biological), XGEVA | Food and Beverage | In-kind items and services | $15.43 | General |
| Category: Bone Health | ||||||
| 02/11/2020 | GENZYME CORPORATION | ELITEK (Biological) | Food and Beverage | In-kind items and services | $17.28 | General |
| Category: Oncology | ||||||
| 02/04/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: ONCOLOGY | ||||||
| 01/16/2020 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: Oncology | ||||||
| 01/14/2020 | Amgen Inc. | XGEVA (Biological) | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 288 | 454 | $160,162 | $37,891 |
| 2022 | 6 | 250 | 375 | $134,348 | $35,464 |
| 2021 | 47 | 1,877 | 41,573 | $2.2M | $497,302 |
| 2020 | 33 | 1,313 | 5,124 | $544,984 | $101,516 |
Total Patients
3,728
Total Services
47,526
Medicare Billing
$672,173
Procedure Codes
94
All Medicare Procedures & Services
94 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 77 | 154 | $64,759 | $15,719 | 24.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 99 | 175 | $52,915 | $12,173 | 23.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 44 | 44 | $26,560 | $5,703 | 21.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 45 | 53 | $10,910 | $2,595 | 23.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 23 | 28 | $5,018 | $1,701 | 33.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 101 | 181 | $72,532 | $19,569 | 27.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 73 | 114 | $32,944 | $8,662 | 26.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 36 | 36 | $20,764 | $4,986 | 24.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 14 | $3,794 | $1,124 | 29.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 15 | 16 | $3,150 | $757.91 | 24.1% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2022 | 14 | 14 | $1,164 | $364.86 | 31.3% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2021 | 16 | 6,200 | $1.1M | $254,312 | 23.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 20 | 3,120 | $216,060 | $48,529 | 22.5% |
| J2505 | Injection, pegfilgrastim, 6 mg | Office | 2021 | 12 | 14 | $150,895 | $32,102 | 21.3% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 33 | 165 | $89,200 | $26,412 | 29.6% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2021 | 25 | 21,000 | $82,935 | $18,610 | 22.4% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2021 | 17 | 6,400 | $81,630 | $17,227 | 21.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 44 | 131 | $72,575 | $17,112 | 23.6% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 83 | 133 | $63,032 | $13,441 | 21.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 50 | 50 | $30,659 | $7,290 | 23.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 61 | 89 | $35,124 | $7,194 | 20.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 35 | 60 | $23,520 | $6,821 | 29.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 31 | 31 | $20,954 | $4,827 | 23.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 136 | 448 | $13,398 | $3,421 | 25.5% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2021 | 130 | 365 | $11,658 | $3,021 | 25.9% |
About Dr. Manjari Pandey, MD
Dr. Manjari Pandey, MD is a Hematology & Oncology healthcare provider based in Danville, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/24/2009. The National Provider Identifier (NPI) number assigned to this provider is 1932339876.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Manjari Pandey, MD has received a total of $3,540 in payments from pharmaceutical and medical device companies, with $27.96 received in 2024. These payments were reported across 131 transactions from 34 companies. The most common payment nature is "Food and Beverage" ($2,350).
As a Medicare-enrolled provider, Pandey has provided services to 3,728 Medicare beneficiaries, totaling 47,526 services with total Medicare billing of $672,173. Data is available for 4 years (2020–2023), covering 94 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Danville, PA
- Active Since 07/24/2009
- Last Updated 09/13/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1932339876
Products in Payments
- LENVIMA (Drug) $1,242
- Optune (Device) $295.77
- TAGRISSO (Drug) $131.71
- Alecensa (Biological) $120.51
- Oncology (Device) $90.42
- IMBRUVICA (Drug) $63.67
- CYRAMZA (Drug) $61.13
- CALQUENCE (Drug) $59.99
- SOLIRIS (Drug) $56.22
- Neulasta (Biological) $56.14
- KEYTRUDA (Biological) $52.63
- JAKAFI (Drug) $46.30
- EMEND (Drug) $43.95
- ELIQUIS (Drug) $42.81
- IMFINZI (Drug) $42.32
- SANCUSO (Drug) $41.49
- Nerlynx (Drug) $40.50
- PADCEV (Biological) $40.49
- Kyprolis (Biological) $40.44
- NINLARO (Drug) $39.41
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Danville
Dr. Joseph Lynch, Md, MD
Hematology & Oncology — Payments: $99,613
Hematology & Oncology $99,613
Mr. Jomel Labayog, Md, MD
Hematology & Oncology — Payments: $14,959
Hematology & Oncology $14,959
Dr. Akintunde Akinleye, M.d, Msc, M.D, MSC
Hematology & Oncology — Payments: $10,304
Hematology & Oncology $10,304
Obed Agyei
Hematology & Oncology — Payments: $7,140
Hematology & Oncology $7,140
Haiyun Wang, Md, MD
Hematology & Oncology — Payments: $6,119
Hematology & Oncology $6,119
Dr. Arej Sawani, M.d, M.D
Hematology & Oncology — Payments: $2,806
Hematology & Oncology $2,806